PubMed HealthSearch

PubMed · 348261

Bromocriptine in Parkinsonism.

Abstract

A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs. High cost and severe psychosis are the main disadvantages of bromocriptine, and, although it is not recommended for patients who are doing well on levodopa, it is the best available drug for hospital use in patients who show late failure with levodopa.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Pearce, J M Pearce. 1978-05-27. Bromocriptine in Parkinsonism.. https://doi.org/10.1136/bmj.1.6124.1402

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Postvaccinal parkinsonism.

A 5-year-old boy, with a history of fever beginning 15 days after a vaccination for measles, developed a rigid-akinetic syndrome 3 days after the fever began. A spinal tap obtained 1 week after the onset of fever showed pleocytosis with a monocellular pattern. A CT scan of the head and EEG did not disclose any abnormality. An MRI performed 3 months after the event, however, showed clear-cut evidence of bilateral substantia nigra lesions, suggesting secondary gliosis. The response to levodopa was good, but adverse reactions appeared early. The child is now 7 years old. Bromocriptine, deprenyl, and levodopa have produced a remarkable improvement of the parkinsonian features.

Bromocriptine